Department of Endocrinology and Metabolism, World Health Organization Collaborating Center for the Diagnosis and Treatment of Thyroid Cancer and Other Thyroid Diseases, University of Pisa, Pisa, Italy.
J Clin Endocrinol Metab. 2012 Feb;97(2):426-35. doi: 10.1210/jc.2011-2046. Epub 2011 Dec 7.
Medullary thyroid carcinoma (MTC) is a calcitonin (CT)-producing C-cell tumor. In hereditary cases, a germline RET mutation is found in 98% of families. Because MTC is cured only if intrathyroidal, prophylactic thyroidectomy is recommended in the gene carrier (GC).
The aim was to determine whether thyroidectomy performed when stimulated CT becomes detectable is as safe as prophylactic thyroidectomy and to identify the serum CT cutoff able to distinguish intrathyroidal from extrathyroidal MTC.
Eighty-four GC were prospectively enrolled; 53 of the 84 underwent total thyroidectomy, one refused surgery, and 30 with normal basal and stimulated CT were under surveillance. The follow-up ranged from 2 to 18 yr.
GC operated on for elevated stimulated CT included 27 GC with a positive peak CT at the screening and four cases who became positive after 4 yr. All of them had intrathyroidal MTC and no node metastases; all were cured after a mean follow-up of 7.5 yr. Among those operated on for detectable basal CT, intrathyroidal tumors were found when CT was below 60 pg/ml, whereas either node metastases or larger tumors were observed when CT was above 60 pg/ml. No correlation among serum CT, age, and type of RET mutation was observed. Thirty GC were still biochemically negative at the annual control.
The time of thyroidectomy in GC with negative CT could be personalized and safely planned when stimulated CT becomes positive, independent of the type of RET mutation and patient's age. In this series, a basal CT below 60 pg/ml was always associated to an intrathyroidal localization of MTC.
甲状腺髓样癌(MTC)是一种降钙素(CT)产生的 C 细胞肿瘤。在遗传性病例中,98%的家族中存在种系 RET 突变。由于只有在甲状腺内才能治愈 MTC,因此建议在基因携带者(GC)中进行预防性甲状腺切除术。
本研究旨在确定在可检测到刺激 CT 时进行的甲状腺切除术是否与预防性甲状腺切除术一样安全,并确定能够区分甲状腺内和甲状腺外 MTC 的血清 CT 截止值。
84 例 GC 前瞻性入组;84 例中的 53 例行全甲状腺切除术,1 例拒绝手术,30 例基础和刺激 CT 正常的患者接受监测。随访时间为 2 至 18 年。
因升高的刺激 CT 而接受手术的 GC 包括 27 例在筛查时 CT 峰值阳性的 GC 和 4 例在 4 年后阳性的病例。所有患者均为甲状腺内 MTC,无淋巴结转移;所有患者在平均 7.5 年的随访后均被治愈。在因可检测到基础 CT 而接受手术的患者中,当 CT 低于 60pg/ml 时发现甲状腺内肿瘤,而当 CT 高于 60pg/ml 时则观察到淋巴结转移或更大的肿瘤。未观察到血清 CT、年龄和 RET 突变类型之间存在相关性。30 例 GC 在年度检查中仍为生化阴性。
在刺激 CT 阳性时,可根据患者的具体情况和安全性计划进行 GC 的甲状腺切除术,这与 RET 突变的类型和患者的年龄无关。在本系列中,基础 CT 低于 60pg/ml 总是与 MTC 的甲状腺内定位相关。